SWOG-nCartes pilot collaboration shows significant expected time savings for study data entry

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The SWOG Cancer Research Network has partnered with cloud clinical research software company nCoup to pilot and deploy the company’s nCartes platform at SWOG sites to help advance data collection. 

In late-phase pilot testing, the results of data entry using the nCartes platform were compared to the current practice of manual data entry, showing significant time savings and improvements in data quality. 

The results were presented at the Society for Clinical Trials 43rd annual meeting.

With nCartes, research sites pull data available in the electronic medical record, such as labs and medications, and automatically transfer the data directly into the research sponsor’s electronic data capture system.

To measure data entry time using the nCartes platform, a study coordinator was timed entering 43 forms. It took 100 minutes to complete all forms, or 2 minutes and 20 seconds per form—a sizable time savings compared to current standard practice. Data quality also improved. 

Table of Contents

YOU MAY BE INTERESTED IN

Tagrisso (osimertinib) demonstrated a sustained, clinically meaningful overall survival benefit at eight years compared to placebo in the adjuvant treatment of patients with early-stage (1B, 2, and 3A) epidermal growth factor receptor-mutated non-small cell lung cancer after complete tumor resection with curative intent, according to the updated exploratory results from the ADAURA phase III trial. 
Congress settled the FY26 question in February, with NCI receiving $7.352 billion, an increase of $128 million over the prior year. After a year in which cancer center directors spent an extraordinary share of their leadership attention defending the research enterprise, that outcome deserves to be called what it was: a win.
OST-HER2-treated patients showed statistically significant benefit in an interim three-year overall survival data analysis when compared with a combined published historical control arm being used for regulatory interactions. The analysis is from the company’s phase IIb trial for the prevention or delay of recurrence in patients with fully resected, pulmonary metastatic osteosarcoma (the “Metastatic Osteosarcoma Program”).

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login